Gesellschaftsrecht / M&A

Healthcare / Life Sciences

IP / IT

Steuern

Noema Pharma

Homburger News

Homburger and Noema Pharma AG

On December 11, 2024, Noema Pharma AG announced that it has successfully closed a Series B extension financing round with an investment from EQT Life Sciences, bringing the total capital raised in the round to CHF 130 m (approx. USD 147 m). With its investment in Noema Pharma, EQT Life Sciences joins the syndicate of previous Series B investors including Forbion, Jeito Capital, Sofinnova Partners, Gilde Healthcare, Polaris Partners, Invus and UPMC Enterprises.
Noema Pharma is a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders characterized by imbalanced neuronal networks. The new financing will support Noema Pharma&#8217;s four active Phase 2 trials, with key data readouts anticipated in 2025.
Homburger AG advised Noema Pharma AG as transaction counsel in this Series B extension financing round. The Homburger team comprised Andreas Müller, Thierry Burckhardt, Thomas Romelli and Rebecca Sigrist (all Corporate / M&amp;A; Healthcare / Life Sciences), Luca Dal Molin (IP / IT; Healthcare / Life Sciences) as well as Stefan Oesterhelt and Laetitia Fracheboud (Tax).

Homburger advised Noema Pharma AG on its Series B extension financing round

Kapitalmarkt

Finanzierungen und Anlageprodukte

Meyer Burger and Homburger

Homburger News 

Share-Image Teamplate Deals-and-Cases

On April 3, 2024, Meyer Burger Technology AG (SIX: MBTN) announced the successful completion of its rights offering, raising gross proceeds of CHF 206.75 m. Shares not subscribed by shareholders were placed with institutional investors at the prevailing market price.
Homburger acted as legal and tax counsel to Meyer Burger in this transaction. The Homburger team was co-led by Dieter Gericke and Daniel Häusermann (both Corporate / M&amp;A, Capital Markets) and included Lorenzo Togni (Capital Markets), Jasmin Künzle, Magda Aref, Hans Glent Abildgaard, Thomas Romelli, Cédric Berger, Oliver Dalla Palma, Daniel Wenzinger and Alexander Giger (all Corporate / M&amp;A, Capital Markets), Miguel Sogo and Oliver Mrose (both Corporate / M&amp;A), Eduard De Zordi and Daniel Hulmann (both Financing and Investment Products) as well as Stefan Oesterhelt (Tax).

Homburger advised Meyer Burger on its CHF 206.75 m rights offering

Homburger and CirCap and Planet First Partners

On November 15, 2023, Nanogence SA closed its Series A financing round, securing financing from a consortium of investors. The consortium was led by CirCap, an investment platform providing strategic private capital to innovative companies in climate-tech, healthcare and education, and included Planet First Partners, a growth-equity sustainable investment platform focusing on supporting high-potential companies in progressing to the growth stage, and the EIC Fund, the venture arm of the European Innovation Council.
Based in Renens, Switzerland, Nanogence developed a proprietary smart catalyst technology, which enhances the binding efficiency of cementitious and inorganic binder systems. Without compromising product performance and without requiring changes in the existing manufacturing processes, the smart catalyst technology is expected to enable reductions of up to 40% in CO2 emissions and up to 20% in costs in applications including cement, concrete and mortar.
Homburger AG advised lead investor CirCap and Planet First Partners on this financing round. The Homburger team was led by Lorenzo Togni and Oriana Schöni and included Léonard Aeschlimann, Thomas Romelli, Aron Belegu and Jana Waldvogel (all Corporate / M&amp;A) as well as Luca Dal Molin and Joel Fink ( both IP / IT).

Homburger advised CirCap and Planet First Partners on their investment in Swiss-based building material innovation start-up Nanogence SA

Thomas
Romelli

Homburger advised Noema Pharma AG on its Series B extension financing round

Homburger advised Meyer Burger on its CHF 206.75 m rights offering

Homburger advised CirCap and Planet First Partners on their investment in Swiss-based building material innovation start-up Nanogence SA

Join the Team

Thomas Romelli

Karriere

Sprachen

Zulassung

Teams

ThomasRomelli

Homburger advised Noema Pharma AG on its Series B extension financing round

Homburger advised Meyer Burger on its CHF 206.75 m rights offering

Homburger advised CirCap and Planet First Partners on their investment in Swiss-based building material innovation start-up Nanogence SA

Join the Team

Thomas Romelli

Karriere

Sprachen

Zulassung

Teams

Thomas
Romelli